ACM
IMVT icon

ADAR1 Capital Management’s Immunovant IMVT Stock Holding History

ADAR1 Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,200
Closed -$291K – 255
2024
Q3 		$291K Buy
+10,200
New +$301K 0.05% 143

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ADAR1 Capital Management's IMVT Position: Q1 2026 in Review

ADAR1 Capital Management increased its Immunovant (IMVT) stake by 8% in Q1 2026, buying an estimated $5.13M and bringing the position to 2,679,010 shares worth $66.5M. The position accounts for 3.92% of the portfolio, ranked #4.

ADAR1 Capital Management first reported a position in IMVT in Q4 2023 and has held it in 10 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • ADAR1 Capital Management held 2,679,010 shares of Immunovant worth $66.5M as of Q1 2026.
  • ADAR1 Capital Management bought 198,042 Immunovant shares in Q1 2026, an estimated $5.13M.
  • Immunovant made up 3.92% of ADAR1 Capital Management's portfolio in Q1 2026, its #4 holding.
  • ADAR1 Capital Management first reported a position in Immunovant in Q4 2023 and has held it in 10 quarters since.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.